Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience by Glass, C. et al.
Bodine Journal
Volume 3
Issue 1 Fall 2010 Article 31
2010
Toxicity of Phase I Radiation Oncology Trials:
Worldwide Experience
C. Glass
Jefferson Medical College
R. B. Den
Thomas Jefferson University and Hospitals
A. P. Dicker
Thomas Jefferson University and Hospitals
Y. R. Lawrence
Thomas Jefferson University and Hospitals
Follow this and additional works at: http://jdc.jefferson.edu/bodinejournal
Part of the Oncology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Bodine Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Glass, C.; Den, R. B.; Dicker, A. P.; and Lawrence, Y. R. (2010) "Toxicity of Phase I Radiation Oncology Trials: Worldwide
Experience," Bodine Journal: Vol. 3: Iss. 1, Article 31.
Available at: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/31
30 BODINEJOURNAL 
Toxicity of Phase I Radiation Oncology 
Trials: Worldwide Experience
Introduction
Informed consent involves understanding the risks and benefits of 
trial enrollment. This is challenging in the phase I setting since true 
quantitative information is never known. We therefore performed 
an analysis of published radiation oncology (RO) phase I trials 
emphasizing patient outcomes. To our knowledge, no such systemic 
analysis has previously been published.
Methods
All phase I and I/II RO clinical trials published in the years 2001, 
2005 and 2009 were identified via a PubMed search. All trials utilized 
radiation therapy, and many also included cytotoxic and/or biologic 
agents. Articles only published in abstract form were excluded, as 
were strict phase II trials, non-English studies, and non-cancer 
pathologies. Variables extracted from the full-text of manuscripts 
included demographics, treatment site, trial design, toxicity, ethical 
and legal considerations, and response rate. In the event of multiple 
adverse events in a single subject, these were calculated as per-study, 
not per-subject.
Results
A total of 119 trials were identified, 17 trials were excluded since 
the manuscript was unobtainable, leaving 102 trials for review (2001, 
27; 2005, 45; and 2009, 30). Of these trials, 59% were performed 
in the USA and 66% were multi-institutional. Sixty-eight percent 
(68%) of trials were phase 1 and 32% were phase I/II trials. The 
most frequent treatment sites were lung 22%, brain 12%, rectal 
11%, and head-and-neck 11%. Seventy-one trials involved dose-
escalating a chemotherapeutic or biologic agent, 21 trials dose-
escalated radiation alone, 2 trials escalated both radiation and/or a 
chemotherapeutic agent, and 8 trials involved no dose-escalation. All 
but 18 trials used a traditional / modified Fibonacci design. A total 
of 4553 subjects were enrolled; 65% were male, with a mean age of 
62. Median or mean follow-up was 25.2 months. There were a total 
of 39 treatment related deaths, and 1881 major toxicities (defined as 
grade 3 or worse excluding death according to CTCAE criteria or 
equivalent) corresponding to an average risk of 0.1% and 41% per 
patient, respectively. The reporting of benefit was inconsistent and 
highly variable preventing meaningful analysis.
Conclusion
Approximately 1500 patients are enrolled per year in radiation 
oncology phase I trials, the majority in the USA. Although the risk 
of death is low (<1%), the risk of major toxicity is significant (>40%). 
These figures have to be considered in the context of expected 
benefit/toxicity of standard of care RO treatment. Although we were 
able to quantify risk, we were unable to quantify benefit. Although 
preliminary, this data sheds light on the risks of patient participation 
in phase I RO trials.
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